Please assess the completion status of the following clinical trial:

Trial Title: Radiosurgery Plus NovoTTF-200A for Metastatic Small Cell Lung Cancer to the Brain

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All subjects must have history of histologically confirmed small cell lung cancer. Brain biopsy is not required unless diagnosis is judged to be in doubt by the treating physician.~* Brain metastases that have not received radiotherapy previously (metastases on post-contrast MRI obtained within six weeks of study entry) deemed to be amenable to SRS.~  * Longest diameter \< 4 cm~* Prior prophylactic cranial irradiation (PCI) is allowed. The maximum allowed dose is 25Gy in 10 fractions.~* Prior systemic therapy is allowed after diagnosis of brain metastases provided that restaging MRI shows measurable intracranial disease.~* Karnofsky Performance Status (KPS) of greater than or equal to 70.~* Age greater than or equal to 18 years.~* Life expectancy greater than 3 months.~* Must receive optimal therapy for extracranial disease and may continue on systemic therapy during TTF administration.~* Ability to operate the NovoTTF-200A device independently or with caregiver aid.~* Previous clinical trial enrollment is allowed.~* Subjects given written informed consent.~Exclusion Criteria:~* History of prior brain metastases.~* Patients with significant edema leading to risk of brain herniation.~* History of prior whole brain radiotherapy (WBRT) other than prophylactic cranial radiation. Prophylactic cranial radiation with a maximum dose of 25 Gy delivered as 10 fractions is allowed. WBRT in excess of 25 Gy (anything over 25 Gy) is not allowed.~* Diffuse Leptomeningeal metastases with radiographic involvement in the brain and/or spinal cord. This does not include local leptomeningeal involvement which is defined as leptomeningeal enhancement within direct contact of targetable metastases.~* Implantable electronic device in the brain.~* Implanted pacemaker, programmable shunts, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias.~* Evidence of increased intracranial pressure (midline shift \> 5mm, clinically significant papilledema, vomiting and nausea, or reduced level of consciousness).~* Known allergies to medical adhesives or hydrogel.~* Currently pregnant or breastfeeding.~* Concurrent brain-directed therapy.~* Insufficient recovery from all active toxicities of prior therapies.~* Women of childbearing potential who are not using an effective method of contraception are excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- NovoTTF-200A device + Stereotactic Radiosurgery (SRS) (Type: EXPERIMENTAL): Patients will undergo SRS treatment followed by continuous TTFields by wearing the NovoTTF-200A device over 18 hours QD. Treatment continues for up to 1 year or until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility